MHG-156 — Xerostomia
Pilocarpine + lipoic acid buccal tablet. Sustained local release with minimal systemic action. FDA proposed 505(b)(2) pathway. Status: IND Ready.
Learn More
07
- demo@example.com
- 15/K, Dhaka London City, LOT
MHG Molecules.fun
Real World Use of Blockchain for Social Good and Science advancement
Tokenizing Drug Development to accelerate and enable IP to reach the market.
Enabling Decentralized Innovation
Problem Statement
Drug development is slow, expensive, and centralized.
Small molecule IP that never makes it to market. Orphan indications underserved. Misallocation of capital - inefficiency & misalignment of incentives. Decentralized inventors limited access to resources. Weak incentives for collaboration.
Our Vision
A decentralized ecosystem where small molecules are tokenized, allowing transparent funding, collaboration, and fair value distribution. Enabling rapid development and new solutions which improve healthcare and lives of people.
Platform Overview
Small Molecules IP is tokenized.
Focussed teams & Partners drive clinical development stages. Token holders share in the upside - clinical value inflections and IP commercialization.
Development Oracle
Each drug passes through stages:
Oracle evaluates stage & value. 10% locked tokens fund validation.
- Wet Lab / Pre-Clinical
- Clinical Phase I Study
- Clinical Phase II Study
- Clinical Phase III Study
- Manufacturing / Distribution
Value to Token Holders
Each molecule company (SPV) is legally bonded to:
- Allocate 30% of lifecycle value
- Buy back & burn tokens
- Linear, ongoing approach
Tokenomics
Transparent Distribution
Token allocation ensures fairness, ecosystem growth, and validation of drug development milestones.
OUR ROADMAP
Molecules.fun Development Timeline
2025
Platform Launch
Q1 2025
Pilot molecules + ecosystem setup
2026
Oracle Integrations
Q2 2026
Smart data feeds & global partnerships
2027
Scaling Buybacks
Q1 2027
Token buyback & burn programs
01
Celfex (Fexofenadine) — Atopic Dermatitis
Once-daily topical (6-in-1): fast itch relief, flare-up prevention, moisturizing, barrier repair, microbiome balance, antibacterial peptide stimulation. Status: Phase 2a/2b Ready.
Learn More
02
CLX-155 — Solid Tumors
Targeted therapy with advantages over Xeloda: extended duration, consistent exposure, safe in liver impairment, potential expanded indications. Status: IND Ready.
Learn More
03
MHG-155A — Glioma
Dual action: HDAC inhibition (valproic acid) + 5-FU DNA/RNA damage. Crosses blood-brain barrier. Extended duration, less variable exposure, safe in liver impairment. Status: PIND Ready.
Learn More
OUR TEAM MEMBER
